|T cell dysfunction in cancer|
DS Thommen, TN Schumacher
Cancer cell 33 (4), 547-562, 2018
|A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade|
DS Thommen, VH Koelzer, P Herzig, A Roller, M Trefny, S Dimeloe, ...
Nature medicine 24 (7), 994-1004, 2018
|Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors|
DS Thommen, J Schreiner, P Müller, P Herzig, A Roller, A Belousov, ...
Cancer immunology research 3 (12), 1344-1355, 2015
|Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade|
P Müller, M Kreuzaler, T Khan, DS Thommen, K Martin, K Glatz, S Savic, ...
Science translational medicine 7 (315), 315ra188-315ra188, 2015
|Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells|
MA Stanczak, SS Siddiqui, MP Trefny, DS Thommen, KF Boligan, ...
The Journal of clinical investigation 128 (11), 4912-4923, 2018
|The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity|
K Martin, P Müller, J Schreiner, SS Prince, D Lardinois, ...
Cancer Immunology, Immunotherapy 63 (9), 925-938, 2014
|CD8+ T cell states in human cancer: insights from single-cell analysis|
AM Van der Leun, DS Thommen, TN Schumacher
Nature Reviews Cancer, 1-15, 2020
|Cancer immunology–development of novel anti-cancer therapies|
SI Rothschild, DS Thommen, W Moersig, P Müller, A Zippelius
Swiss medical weekly 145 (0506), 2015
|Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol. Res. 2015; 3: 1344–1355 …|
DS Thommen, J Schreiner, P Muller, P Herzig, A Roller, A Belousov, ...
CIR-15-0097.[PubMed][CrossRef][Google Scholar], 0
|Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor|
J Schreiner, DS Thommen, P Herzig, M Bacac, C Klein, A Roller, ...
Oncoimmunology 5 (2), e1062969, 2016
|Digital image analysis improves precision of PD‐L1 scoring in cutaneous melanoma|
VH Koelzer, A Gisler, JC Hanhart, J Griss, SN Wagner, N Willi, ...
Histopathology 73 (3), 397-406, 2018
|Antibody phage display assisted identification of junction plakoglobin as a potential biomarker for atherosclerosis|
S Cooksley-Decasper, H Reiser, DS Thommen, B Biedermann, ...
PloS one 7 (10), e47985, 2012
|Tumor-derived TGF-β inhibits mitochondrial respiration to suppress IFN-γ production by human CD4+ T cells|
S Dimeloe, P Gubser, J Loeliger, C Frick, L Develioglu, M Fischer, ...
Science signaling 12 (599), eaav3334, 2019
|A variant of a killer cell immunoglobulin-like receptor is associated with resistance to PD-1 blockade in lung cancer|
MP Trefny, SI Rothschild, F Uhlenbrock, D Rieder, B Kasenda, ...
Clinical Cancer Research 25 (10), 3026-3034, 2019
|Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ|
ME Hoekstra, L Bornes, FE Dijkgraaf, D Philips, IN Pardieck, M Toebes, ...
Nature Cancer 1 (3), 291-301, 2020
|Two preferentially expressed proteins protect vascular endothelial cells from an attack by peptide-specific CTL|
DS Thommen, H Schuster, M Keller, S Kapoor, AO Weinzierl, ...
The Journal of Immunology 188 (11), 5283-5292, 2012
|Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med. 2015; 7 (315): 315ra188|
P Muller, M Kreuzaler, T Khan, DS Thommen, K Martin, K Glatz
|The first shall (be) last: understanding durable T cell responses in immunotherapy|
Immunity 50 (1), 6-8, 2019
|66P Highly exhausted PD-1hi T cell subsets in human NSCLC are co-defined by the predominant expression of distinct inhibitory receptors and correlate with clinical outcome|
D Thommen, F Uhlenbrock, P Herzig, SS Prince, W Moersig, D Lardinois, ...
Journal of Thoracic Oncology 11 (4), S83, 2016
|Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists|
C Klein, V Karanikas, P Umana, A Zippelius, DS Thommen, J Schreiner
US Patent 10,781,262, 2020